Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy

Thomas Meier, Thomas Voit, Ulrike Schara, Chiara S M Straathof, M. Grazia D'Angelo, Günther Bernert, Jean Marie Cuisset, Richard S. Finkel, Nathalie Goemans, Christian Rummey, Mika Leinonen, Paolo Spagnolo, Gunnar M. Buyse, G. Bernert, F. Knipp, G. M. Buyse, N. Goemans, M. van den Hauwe, T. Voit, V. DopplerT. Gidaro, J. M. Cuisset, S. Coopman, U. Schara, S. Lutz, J. Kirschner, S. Borell, M. Will, M. G. D'Angelo, E. Brighina, S. Gandossini, K. Gorni, E. Falcier, L. Politano, P. D'Ambrosio, A. Taglia, J. J G M Verschuuren, C. S M Straathof, J. J. Vílchez Padilla, N. Muelas Gómez, T. Sejersen, M. Hovmöller, P. Y. Jeannet, C. Bloetzer, S. Iannaccone, D. Castro, G. Tennekoon, R. Finkel, C. Bönnemann, C. McDonald, E. Henricson, N. Joyce, Craig M. McDonald, S. Apkon, R. C. Richardson

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

In Duchenne muscular dystrophy (DMD), progressive loss of respiratory function leads to restrictive pulmonary disease and places patients at significant risk for severe respiratory complications. Of particular concern are ineffective cough, secretion retention and recurrent respiratory tract infections. In a Phase 3 randomized controlled study (DMD Long-term Idebenone Study, DELOS) in DMD patients 10–18 years of age and not taking concomitant glucocorticoid steroids, idebenone (900 mg/day) reduced significantly the loss of respiratory function over a 1-year study period. In a post-hoc analysis of DELOS we found that more patients in the placebo group compared to the idebenone group experienced bronchopulmonary adverse events (BAEs): placebo: 17 of 33 patients, 28 events; idebenone: 6 of 31 patients, 7 events. The hazard ratios (HR) calculated “by patient” (HR 0.33, p = 0.0187) and for “all BAEs” (HR 0.28, p = 0.0026) indicated a clear idebenone treatment effect. The overall duration of BAEs was 222 days (placebo) vs. 82 days (idebenone). In addition, there was also a difference in the use of systemic antibiotics utilized for the treatment of BAEs. In the placebo group, 13 patients (39.4%) reported 17 episodes of antibiotic use compared to 7 patients (22.6%) reporting 8 episodes of antibiotic use in the idebenone group. Furthermore, patients in the placebo group used systemic antibiotics for longer (105 days) compared to patients in the idebenone group (65 days). This post-hoc analysis of DELOS indicates that the protective effect of idebenone on respiratory function is associated with a reduced risk of bronchopulmonary complications and a reduced need for systemic antibiotics.

Original languageEnglish (US)
Pages (from-to)473-480
Number of pages8
JournalNeuromuscular Disorders
Volume26
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Duchenne Muscular Dystrophy
Placebos
Anti-Bacterial Agents
idebenone
Cough
Respiratory Tract Infections
Glucocorticoids
Lung Diseases
Steroids

Keywords

  • Airway infection
  • Duchenne muscular dystrophy
  • Idebenone
  • Respiratory function

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Neurology
  • Clinical Neurology
  • Genetics(clinical)

Cite this

Meier, T., Voit, T., Schara, U., Straathof, C. S. M., D'Angelo, M. G., Bernert, G., ... Richardson, R. C. (2016). Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy. Neuromuscular Disorders, 26(8), 473-480. https://doi.org/10.1016/j.nmd.2016.05.008

Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy. / Meier, Thomas; Voit, Thomas; Schara, Ulrike; Straathof, Chiara S M; D'Angelo, M. Grazia; Bernert, Günther; Cuisset, Jean Marie; Finkel, Richard S.; Goemans, Nathalie; Rummey, Christian; Leinonen, Mika; Spagnolo, Paolo; Buyse, Gunnar M.; Bernert, G.; Knipp, F.; Buyse, G. M.; Goemans, N.; van den Hauwe, M.; Voit, T.; Doppler, V.; Gidaro, T.; Cuisset, J. M.; Coopman, S.; Schara, U.; Lutz, S.; Kirschner, J.; Borell, S.; Will, M.; D'Angelo, M. G.; Brighina, E.; Gandossini, S.; Gorni, K.; Falcier, E.; Politano, L.; D'Ambrosio, P.; Taglia, A.; Verschuuren, J. J G M; Straathof, C. S M; Vílchez Padilla, J. J.; Muelas Gómez, N.; Sejersen, T.; Hovmöller, M.; Jeannet, P. Y.; Bloetzer, C.; Iannaccone, S.; Castro, D.; Tennekoon, G.; Finkel, R.; Bönnemann, C.; McDonald, C.; Henricson, E.; Joyce, N.; McDonald, Craig M.; Apkon, S.; Richardson, R. C.

In: Neuromuscular Disorders, Vol. 26, No. 8, 01.08.2016, p. 473-480.

Research output: Contribution to journalArticle

Meier, T, Voit, T, Schara, U, Straathof, CSM, D'Angelo, MG, Bernert, G, Cuisset, JM, Finkel, RS, Goemans, N, Rummey, C, Leinonen, M, Spagnolo, P, Buyse, GM, Bernert, G, Knipp, F, Buyse, GM, Goemans, N, van den Hauwe, M, Voit, T, Doppler, V, Gidaro, T, Cuisset, JM, Coopman, S, Schara, U, Lutz, S, Kirschner, J, Borell, S, Will, M, D'Angelo, MG, Brighina, E, Gandossini, S, Gorni, K, Falcier, E, Politano, L, D'Ambrosio, P, Taglia, A, Verschuuren, JJGM, Straathof, CSM, Vílchez Padilla, JJ, Muelas Gómez, N, Sejersen, T, Hovmöller, M, Jeannet, PY, Bloetzer, C, Iannaccone, S, Castro, D, Tennekoon, G, Finkel, R, Bönnemann, C, McDonald, C, Henricson, E, Joyce, N, McDonald, CM, Apkon, S & Richardson, RC 2016, 'Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy', Neuromuscular Disorders, vol. 26, no. 8, pp. 473-480. https://doi.org/10.1016/j.nmd.2016.05.008
Meier T, Voit T, Schara U, Straathof CSM, D'Angelo MG, Bernert G et al. Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy. Neuromuscular Disorders. 2016 Aug 1;26(8):473-480. https://doi.org/10.1016/j.nmd.2016.05.008
Meier, Thomas ; Voit, Thomas ; Schara, Ulrike ; Straathof, Chiara S M ; D'Angelo, M. Grazia ; Bernert, Günther ; Cuisset, Jean Marie ; Finkel, Richard S. ; Goemans, Nathalie ; Rummey, Christian ; Leinonen, Mika ; Spagnolo, Paolo ; Buyse, Gunnar M. ; Bernert, G. ; Knipp, F. ; Buyse, G. M. ; Goemans, N. ; van den Hauwe, M. ; Voit, T. ; Doppler, V. ; Gidaro, T. ; Cuisset, J. M. ; Coopman, S. ; Schara, U. ; Lutz, S. ; Kirschner, J. ; Borell, S. ; Will, M. ; D'Angelo, M. G. ; Brighina, E. ; Gandossini, S. ; Gorni, K. ; Falcier, E. ; Politano, L. ; D'Ambrosio, P. ; Taglia, A. ; Verschuuren, J. J G M ; Straathof, C. S M ; Vílchez Padilla, J. J. ; Muelas Gómez, N. ; Sejersen, T. ; Hovmöller, M. ; Jeannet, P. Y. ; Bloetzer, C. ; Iannaccone, S. ; Castro, D. ; Tennekoon, G. ; Finkel, R. ; Bönnemann, C. ; McDonald, C. ; Henricson, E. ; Joyce, N. ; McDonald, Craig M. ; Apkon, S. ; Richardson, R. C. / Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy. In: Neuromuscular Disorders. 2016 ; Vol. 26, No. 8. pp. 473-480.
@article{ec8b597a75f947ffa9bd2f2729fc132c,
title = "Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy",
abstract = "In Duchenne muscular dystrophy (DMD), progressive loss of respiratory function leads to restrictive pulmonary disease and places patients at significant risk for severe respiratory complications. Of particular concern are ineffective cough, secretion retention and recurrent respiratory tract infections. In a Phase 3 randomized controlled study (DMD Long-term Idebenone Study, DELOS) in DMD patients 10–18 years of age and not taking concomitant glucocorticoid steroids, idebenone (900 mg/day) reduced significantly the loss of respiratory function over a 1-year study period. In a post-hoc analysis of DELOS we found that more patients in the placebo group compared to the idebenone group experienced bronchopulmonary adverse events (BAEs): placebo: 17 of 33 patients, 28 events; idebenone: 6 of 31 patients, 7 events. The hazard ratios (HR) calculated “by patient” (HR 0.33, p = 0.0187) and for “all BAEs” (HR 0.28, p = 0.0026) indicated a clear idebenone treatment effect. The overall duration of BAEs was 222 days (placebo) vs. 82 days (idebenone). In addition, there was also a difference in the use of systemic antibiotics utilized for the treatment of BAEs. In the placebo group, 13 patients (39.4{\%}) reported 17 episodes of antibiotic use compared to 7 patients (22.6{\%}) reporting 8 episodes of antibiotic use in the idebenone group. Furthermore, patients in the placebo group used systemic antibiotics for longer (105 days) compared to patients in the idebenone group (65 days). This post-hoc analysis of DELOS indicates that the protective effect of idebenone on respiratory function is associated with a reduced risk of bronchopulmonary complications and a reduced need for systemic antibiotics.",
keywords = "Airway infection, Duchenne muscular dystrophy, Idebenone, Respiratory function",
author = "Thomas Meier and Thomas Voit and Ulrike Schara and Straathof, {Chiara S M} and D'Angelo, {M. Grazia} and G{\"u}nther Bernert and Cuisset, {Jean Marie} and Finkel, {Richard S.} and Nathalie Goemans and Christian Rummey and Mika Leinonen and Paolo Spagnolo and Buyse, {Gunnar M.} and G. Bernert and F. Knipp and Buyse, {G. M.} and N. Goemans and {van den Hauwe}, M. and T. Voit and V. Doppler and T. Gidaro and Cuisset, {J. M.} and S. Coopman and U. Schara and S. Lutz and J. Kirschner and S. Borell and M. Will and D'Angelo, {M. G.} and E. Brighina and S. Gandossini and K. Gorni and E. Falcier and L. Politano and P. D'Ambrosio and A. Taglia and Verschuuren, {J. J G M} and Straathof, {C. S M} and {V{\'i}lchez Padilla}, {J. J.} and {Muelas G{\'o}mez}, N. and T. Sejersen and M. Hovm{\"o}ller and Jeannet, {P. Y.} and C. Bloetzer and S. Iannaccone and D. Castro and G. Tennekoon and R. Finkel and C. B{\"o}nnemann and C. McDonald and E. Henricson and N. Joyce and McDonald, {Craig M.} and S. Apkon and Richardson, {R. C.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.nmd.2016.05.008",
language = "English (US)",
volume = "26",
pages = "473--480",
journal = "Neuromuscular Disorders",
issn = "0960-8966",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy

AU - Meier, Thomas

AU - Voit, Thomas

AU - Schara, Ulrike

AU - Straathof, Chiara S M

AU - D'Angelo, M. Grazia

AU - Bernert, Günther

AU - Cuisset, Jean Marie

AU - Finkel, Richard S.

AU - Goemans, Nathalie

AU - Rummey, Christian

AU - Leinonen, Mika

AU - Spagnolo, Paolo

AU - Buyse, Gunnar M.

AU - Bernert, G.

AU - Knipp, F.

AU - Buyse, G. M.

AU - Goemans, N.

AU - van den Hauwe, M.

AU - Voit, T.

AU - Doppler, V.

AU - Gidaro, T.

AU - Cuisset, J. M.

AU - Coopman, S.

AU - Schara, U.

AU - Lutz, S.

AU - Kirschner, J.

AU - Borell, S.

AU - Will, M.

AU - D'Angelo, M. G.

AU - Brighina, E.

AU - Gandossini, S.

AU - Gorni, K.

AU - Falcier, E.

AU - Politano, L.

AU - D'Ambrosio, P.

AU - Taglia, A.

AU - Verschuuren, J. J G M

AU - Straathof, C. S M

AU - Vílchez Padilla, J. J.

AU - Muelas Gómez, N.

AU - Sejersen, T.

AU - Hovmöller, M.

AU - Jeannet, P. Y.

AU - Bloetzer, C.

AU - Iannaccone, S.

AU - Castro, D.

AU - Tennekoon, G.

AU - Finkel, R.

AU - Bönnemann, C.

AU - McDonald, C.

AU - Henricson, E.

AU - Joyce, N.

AU - McDonald, Craig M.

AU - Apkon, S.

AU - Richardson, R. C.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - In Duchenne muscular dystrophy (DMD), progressive loss of respiratory function leads to restrictive pulmonary disease and places patients at significant risk for severe respiratory complications. Of particular concern are ineffective cough, secretion retention and recurrent respiratory tract infections. In a Phase 3 randomized controlled study (DMD Long-term Idebenone Study, DELOS) in DMD patients 10–18 years of age and not taking concomitant glucocorticoid steroids, idebenone (900 mg/day) reduced significantly the loss of respiratory function over a 1-year study period. In a post-hoc analysis of DELOS we found that more patients in the placebo group compared to the idebenone group experienced bronchopulmonary adverse events (BAEs): placebo: 17 of 33 patients, 28 events; idebenone: 6 of 31 patients, 7 events. The hazard ratios (HR) calculated “by patient” (HR 0.33, p = 0.0187) and for “all BAEs” (HR 0.28, p = 0.0026) indicated a clear idebenone treatment effect. The overall duration of BAEs was 222 days (placebo) vs. 82 days (idebenone). In addition, there was also a difference in the use of systemic antibiotics utilized for the treatment of BAEs. In the placebo group, 13 patients (39.4%) reported 17 episodes of antibiotic use compared to 7 patients (22.6%) reporting 8 episodes of antibiotic use in the idebenone group. Furthermore, patients in the placebo group used systemic antibiotics for longer (105 days) compared to patients in the idebenone group (65 days). This post-hoc analysis of DELOS indicates that the protective effect of idebenone on respiratory function is associated with a reduced risk of bronchopulmonary complications and a reduced need for systemic antibiotics.

AB - In Duchenne muscular dystrophy (DMD), progressive loss of respiratory function leads to restrictive pulmonary disease and places patients at significant risk for severe respiratory complications. Of particular concern are ineffective cough, secretion retention and recurrent respiratory tract infections. In a Phase 3 randomized controlled study (DMD Long-term Idebenone Study, DELOS) in DMD patients 10–18 years of age and not taking concomitant glucocorticoid steroids, idebenone (900 mg/day) reduced significantly the loss of respiratory function over a 1-year study period. In a post-hoc analysis of DELOS we found that more patients in the placebo group compared to the idebenone group experienced bronchopulmonary adverse events (BAEs): placebo: 17 of 33 patients, 28 events; idebenone: 6 of 31 patients, 7 events. The hazard ratios (HR) calculated “by patient” (HR 0.33, p = 0.0187) and for “all BAEs” (HR 0.28, p = 0.0026) indicated a clear idebenone treatment effect. The overall duration of BAEs was 222 days (placebo) vs. 82 days (idebenone). In addition, there was also a difference in the use of systemic antibiotics utilized for the treatment of BAEs. In the placebo group, 13 patients (39.4%) reported 17 episodes of antibiotic use compared to 7 patients (22.6%) reporting 8 episodes of antibiotic use in the idebenone group. Furthermore, patients in the placebo group used systemic antibiotics for longer (105 days) compared to patients in the idebenone group (65 days). This post-hoc analysis of DELOS indicates that the protective effect of idebenone on respiratory function is associated with a reduced risk of bronchopulmonary complications and a reduced need for systemic antibiotics.

KW - Airway infection

KW - Duchenne muscular dystrophy

KW - Idebenone

KW - Respiratory function

UR - http://www.scopus.com/inward/record.url?scp=84969972170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969972170&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2016.05.008

DO - 10.1016/j.nmd.2016.05.008

M3 - Article

C2 - 27238057

AN - SCOPUS:84969972170

VL - 26

SP - 473

EP - 480

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

SN - 0960-8966

IS - 8

ER -